Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Stock Information for Issuer Direct Corporation
Loading
Please wait while we load your information from QuoteMedia.